EN DE
Watch Captor Therapeutics S.A. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Captor Therapeutics S.A. (CTX) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Captor Therapeutics S.A. stock PLN 30.21, price PLN 52.40, that is 42.3% below the price, quality 27 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare PL · ISIN PLCPTRT00014

CT Captor Therapeutics S.A. logo Thin data Nov 10, 2026

Captor Therapeutics S.A.

CTX · WAR
Very expensive, weak quality

Our calculation puts a fair price 42% below what the stock costs today.

Low debt
Revenue last quarter 19% below a year ago.
Fair value 30.21 PLN · Strongly overvalued
Quality 27/100
Weak Growth (revenue 3y −20.2 %/yr in PLN)
Negative free cash flow
Trails peers (1/7)
Narrow moat 8/100 · thin data
Thin data
Estimate
Watch Captor Therapeutics S.A. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

202.00 PLN 31.40 PLN Fair Value 30.21 PLN Jul 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range 31.40 PLN – 202.00 PLN · fair‑value band 22.66 PLN – 37.76 PLN · the 52.40 PLN price screens above the 30.21 PLN fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Captor Therapeutics in your weekly email

Every Wednesday you see whether Captor Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, develops therapeutic molecules for treating oncological and autoimmune diseases in Poland.

Show moreShow less

The company offers targeted protein degradation technology that utilizes the Optigrade drug discovery platform to overcome the limitations of inhibitors and antibody drugs by destroying disease-causing proteins that are resistant to available therapeutics.

It develops viadrudomide, which is in a Phase 1 clinical trial for hepatocellular carcinoma (HCC), lung cancer, and rare cancers; vratitoclax, a bifunctional MCL-1 protein degrader that is in the CTA-enabling stage for liquid and solid tumors; CT-02B, a NEK7 degrader that is in preclinical trials for neuroinflammation indications in Parkinson's disease, amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS); CT-02S, a NEK7 degrader that is in preclinical trials for systemic autoimmunity indications in inflammatory bowel diseases (IBD), gout, and dermatological diseases; and CT-05, a PKCtheta degrader that is in preclinical trials for autoimmunity, transplantation, and metabolism indications.

In addition, the company's candidates in the discovery phase include an undisclosed project for oncology, autoimmunity, CNS, and rare indications; and novel E3 ligases for oncology and autoimmunity indications.

Captor Therapeutics Spolka Akcyjna was incorporated in 2015 and is headquartered in Wroclaw, Poland.

Stock analysis

Captor Therapeutics S.A. (CTX) currently trades at 52.40 PLN, while our estimate is 30.21 PLN, 42% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 22.66 PLN (bear) to 37.76 PLN (bull), the price of 52.40 PLN sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 27/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Captor Therapeutics S.A. reported revenue of 4.7M PLN in FY2025 versus 4.0M PLN in FY2021, a compound +4.0%/yr. Reported net income was −42.0M PLN in FY2025.

Key figures

Market cap 318M PLN (≈ $81.4M) Micro · EPS (TTM) −8.05 PLN · Return on equity −80.6% · Return on assets (EBIT) −63.0% (5-year average) · Operating margin −791% · Revenue (TTM) 2.0M PLN · Revenue growth (YoY) −18.7% · Free cash flow −36.5M PLN.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 40% below its 52-week high and 19% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −42%, CTX screens richer than that median.

Fair Value

Bear 22.66 PLN Fair Value 30.21 PLN Bull 37.76 PLN
Price 52.40 PLN · Downside -42.3%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 27/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 4
Are margins and returns getting better?
Cashflow 8
Do the profits arrive as real cash?
Financial strength 70
Debt, balance sheet and risk of trouble
Investment 95
Does it invest with discipline instead of growing at any price?
Low Volatility 73
How calm the share price moves, does not count
Price momentum 26
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 33
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 29/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−70.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−20.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+26.2%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+33.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−840.2% (2020) → −1,141.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

CTX screens overvalued: fair value 42% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Captor Therapeutics S.A. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 0/5 measures
Overall it trails its industry peers.
Valuation
Quality Score 27 · Bottom 25%
Fair Value upside −42.3% · Bottom 25%
Profitability
Return on assets −104.9% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −18.7% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 13.56× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs CTX
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs CTX
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs CTX
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs CTX
argenx SE ARGX $971.55 $908.40 −7% vs CTX
CSL Limited CSL A$201.68 A$181.40 −10% vs CTX
Moderna, Inc MRNA $250.83 $158.70 −37% vs CTX
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs CTX
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs CTX
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs CTX

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Captor Therapeutics S.A.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Captor Therapeutics S.A. Fair Value". https://www.fairvalue-calculator.com/stock/CTX

Frequently asked questions

Is Captor Therapeutics S.A. (CTX) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is 30.21 PLN versus a price of 52.40 PLN, about 42% lower (overvalued).
What is the fair value of CTX?
Our estimate for Captor Therapeutics S.A. is 30.21 PLN (as of Nov 10, 2026), built from audited fundamentals. The current price: 52.40 PLN.
What is the quality score of CTX?
Captor Therapeutics S.A. has a Quality Score of 27/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Captor Therapeutics S.A. (CTX)?
Our calculated price target is the estimate of 30.21 PLN (as of Nov 10, 2026). Cautious scenario 22.66 PLN, optimistic scenario 37.76 PLN. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Captor Therapeutics S.A. stock forecast for 2026?
Our estimate puts fair value at 30.21 PLN, about 42% lower versus a price of 52.40 PLN (overvalued). Cautious scenario 22.66 PLN, optimistic scenario 37.76 PLN. The calculation is refreshed regularly with new filings.
What is the revenue of Captor Therapeutics S.A. (CTX)?
Captor Therapeutics S.A. reported trailing-twelve-month revenue of about 2.0M PLN (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Captor Therapeutics S.A. (CTX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Captor Therapeutics S.A. it is 30.21 PLN per share (as of Nov 10, 2026), against a price of 52.40 PLN.
Is Captor Therapeutics S.A. stock overvalued or undervalued in 2026?
As of Nov 10, 2026, CTX trades above its calculated fair value: price 52.40 PLN, fair value 30.21 PLN, a gap of about −42% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CTX?
No. The price is what the market pays today (52.40 PLN); the fair value is what the company's own numbers justify (30.21 PLN). For Captor Therapeutics S.A. the two are 22.19 PLN per share apart. That gap is exactly why we show both numbers side by side.
How much is Captor Therapeutics S.A. worth?
The market values Captor Therapeutics S.A. at about 318M PLN (market capitalisation, as of Nov 10, 2026). Per share that is 52.40 PLN; our models calculate a fair value of 30.21 PLN per share.
What do the bullish and bearish scenarios say about CTX?
Our models span a range for Captor Therapeutics S.A.: cautious scenario 22.66 PLN, base 30.21 PLN, optimistic 37.76 PLN per share (as of Nov 10, 2026, price 52.40 PLN). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Captor Therapeutics S.A. (CTX)?
Balance-sheet figures for Captor Therapeutics S.A. (as of Nov 10, 2026): return on equity −80.6%. They feed the Quality Score of 27/100, which measures business quality independently of the share price.
How far is CTX from its 52-week high?
Captor Therapeutics S.A. trades at 52.40 PLN, about 40% below its 52-week high of 87.60 PLN and 19% above the low of 44.10 PLN (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of 30.21 PLN is for.
Which stocks are comparable to Captor Therapeutics S.A.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Captor Therapeutics S.A. stock attractive at the current price?
The data as of Nov 10, 2026: price 52.40 PLN, calculated fair value 30.21 PLN (−42%), Quality Score 27/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Captor Therapeutics S.A. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Captor Therapeutics S.A. (CTX)?
The closing price on Nov 10, 2026 was 52.40 PLN. Our estimate is 30.21 PLN, about 42% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Captor Therapeutics S.A. right now?
The price sits above even our optimistic bull case (37.76 PLN). The favourable scenario is already priced in. Weak quality (27/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Captor Therapeutics S.A.

How large is the market capitalisation of Captor Therapeutics S.A. (CTX)?
The market capitalisation of Captor Therapeutics S.A. is 318M PLN (≈ $81.4M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Captor Therapeutics S.A. (CTX)?
Earnings per share at Captor Therapeutics S.A. are −8.05 PLN. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Captor Therapeutics S.A. (CTX)?
The return on equity (ROE) of Captor Therapeutics S.A. is −80.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Captor Therapeutics S.A. (CTX)?
On an EBIT basis the return on assets of Captor Therapeutics S.A. is −63.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Captor Therapeutics S.A. (CTX)?
The operating margin of Captor Therapeutics S.A. is −791% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Captor Therapeutics S.A. (CTX)?
Revenue at Captor Therapeutics S.A. is growing −18.7% versus a year earlier (3y avg −20.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Captor Therapeutics S.A. (CTX) generate?
The free cash flow of Captor Therapeutics S.A. is −36.5M PLN (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Captor Therapeutics S.A. (CTX) hold?
Captor Therapeutics S.A. holds more cash than debt, 7.1M PLN net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Captor Therapeutics S.A. in the live analysis

One click puts Captor Therapeutics S.A. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.